# ADICET BIO INC (ACET)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/ACET/

- Reporting holders: 57
- Reported value: $59.8M
- Shares held by institutions: 6,824,334 of 9,361,490 outstanding
- Held through calls: 0.3%
- Held through puts: 1.1%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [RA CAPITAL MANAGEMENT, L.P.](https://holderbook.com/funds/1346824-ra-capital-management-l-p/) | $8.1M | 932,624 | 0.1% | 3 |
| [CITADEL ADVISORS LLC](https://holderbook.com/funds/1423053-citadel-advisors-llc/) | $8.1M | 865,476 | 0.0% | 3 |
| [ORBIMED ADVISORS LLC](https://holderbook.com/funds/1055951-orbimed-advisors-llc/) | $7.3M | 844,787 | 0.1% | 3 |
| [FRANKLIN RESOURCES INC](https://holderbook.com/funds/38777-franklin-resources-inc/) | $5.4M | 626,571 | 0.0% | 3 |
| [Stonepine Capital Management, LLC](https://holderbook.com/funds/1440771-stonepine-capital-management-llc/) | $4.2M | 491,036 | 1.1% | 3 |
| [VANGUARD CAPITAL MANAGEMENT LLC](https://holderbook.com/funds/2100119-vanguard-capital-management-llc/) | $3.0M | 343,228 | 0.0% | 2 |
| [ADAGE CAPITAL PARTNERS GP, L.L.C.](https://holderbook.com/funds/1165408-adage-capital-partners-gp-l-l-c/) | $2.4M | 274,375 | 0.0% | 3 |
| [RENAISSANCE TECHNOLOGIES LLC](https://holderbook.com/funds/1037389-renaissance-technologies-llc/) | $2.3M | 265,945 | 0.0% | 3 |
| [Alyeska Investment Group, L.P.](https://holderbook.com/funds/1453072-alyeska-investment-group-l-p/) | $1.8M | 203,799 | 0.0% | 3 |
| [Schonfeld Strategic Advisors LLC](https://holderbook.com/funds/1665241-schonfeld-strategic-advisors-llc/) | $1.7M | 195,514 | 0.0% | 1 |
| [Carlyle Group Inc.](https://holderbook.com/funds/1527166-carlyle-group-inc/) | $1.6M | 184,295 | 0.0% | 3 |
| [NEXTBio Capital Management LP](https://holderbook.com/funds/2038158-nextbio-capital-management-lp/) | $1.4M | 157,827 | 0.6% | 3 |
| [ACADIAN ASSET MANAGEMENT LLC](https://holderbook.com/funds/916542-acadian-asset-management-llc/) | $1.1M | 124,832 | 0.0% | 3 |
| [TWO SIGMA INVESTMENTS, LP](https://holderbook.com/funds/1179392-two-sigma-investments-lp/) | $836.7K | 96,839 | 0.0% | 3 |
| [GEODE CAPITAL MANAGEMENT, LLC](https://holderbook.com/funds/1214717-geode-capital-management-llc/) | $826.7K | 95,634 | 0.0% | 3 |
| [DAFNA Capital Management LLC](https://holderbook.com/funds/1389933-dafna-capital-management-llc/) | $810.5K | 93,812 | 0.2% | 3 |
| [BRIDGEWAY CAPITAL MANAGEMENT, LLC](https://holderbook.com/funds/1107261-bridgeway-capital-management-llc/) | $742.7K | 85,959 | 0.0% | 1 |
| [MARSHALL WACE, LLP](https://holderbook.com/funds/1318757-marshall-wace-llp/) | $686.8K | 79,488 | 0.0% | 1 |
| [Trexquant Investment LP](https://holderbook.com/funds/1633445-trexquant-investment-lp/) | $673.9K | 78,002 | 0.0% | 2 |
| [STATE STREET CORP](https://holderbook.com/funds/93751-state-street-corp/) | $625.9K | 72,444 | 0.0% | 3 |
| [JANE STREET GROUP, LLC](https://holderbook.com/funds/1595888-jane-street-group-llc/) | $609.6K | 70,561 | 0.0% | 2 |
| [Burkehill Global Management, LP](https://holderbook.com/funds/1904549-burkehill-global-management-lp/) | $540.0K | 62,500 | 0.0% | 3 |
| [BlackRock, Inc.](https://holderbook.com/funds/2012383-blackrock-inc/) | $536.8K | 62,126 | 0.0% | 3 |
| [REGENERON PHARMACEUTICALS, INC.](https://holderbook.com/funds/872589-regeneron-pharmaceuticals-inc/) | $522.8K | 60,511 | 0.3% | 1 |
| [Rangeley Capital, LLC](https://holderbook.com/funds/1517796-rangeley-capital-llc/) | $439.7K | 50,892 | 0.4% | 3 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 57 | $59.8M |
| Q1 2026 | 50 | $44.0M |
| Q4 2025 | 49 | $56.9M |
| Q3 2025 | 55 | $41.6M |
| Q2 2025 | 48 | $31.5M |
| Q1 2025 | 56 | $42.1M |
| Q4 2024 | 62 | $55.5M |
| Q3 2024 | 63 | $82.4M |
| Q2 2024 | 87 | $77.5M |
| Q1 2024 | 99 | $196.0M |
| Q4 2023 | 77 | $68.5M |
| Q3 2023 | 83 | $48.9M |